Prabhudas Lilladher's research report on Sun Pharmaceutical Industries
Our FY24/FY25 earnings estimates stands increased by ~3%. Sun Pharma (SUNP) Q1FY24 EBIDTA was 10% above our estimate, aided by gRevlimid and lower other expenses. Overall specialty sales, GMs continue to remain healthy. Over last few years SUNP dependency on US generics has reduced and company’s growth is more functional on specialty, RoW and domestic pharma business that has strong growth visibility. Furthermore, acquisition of Concert Pharma along with progress of other pipelines provides visibility to SUNP’s specialty pipeline beyond FY25.
Outlook
We maintain ‘BUY’ rating at TP of Rs.1265 (Rs1140 earlier) based on 27x FY25E earnings. SUNP remains our top pick in large cap space.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
